Gene therapy delivers lasting immune protection in children with rare disorder
Long-term follow-up shows 95% success rate, no serious complications in largest and longest ADA-SCID gene therapy study to date.
Long-term follow-up shows 95% success rate, no serious complications in largest and longest ADA-SCID gene therapy study to date.
